FTPR44

Nom de l'organisation

Labomar S.p.A.

SRN

IT-MF-000007965

Statut du fabricant

Actif

Santé des certificats sur le portefeuille de ce fabricant.

5 avertissements enregistrés — faire défiler le panneau pour tout voir.

• CW010

  EUDAMED n'a pas publié de description pour ce code.
• CW007

  EUDAMED n'a pas publié de description pour ce code.
• CW032

  EUDAMED n'a pas publié de description pour ce code.
• CW135

  EUDAMED n'a pas publié de description pour ce code.
• CW999

  Before administering to children under three years of age, it is recommended to seek advice from your doctor. In children under three years of age, if symptoms persist and worsen after first two days of treatment, consult your doctor. If you do not notice appreciable results after a short period of treatment (7 days), contact your doctor, in any case do not use for more than 15 days. Close the bottle carefully after use. Do not take the product it if you are allergic, intolerant or hypersensitive to any of its components. Do not use for purposes other than that for which the product is intended. No side effects associated by used the device have been observed. If you notice the appearance of side effects, inform your doctor. Expiry date refers to the product in its intact packaging and properly stored. Wash carefully the measuring cup after use. Since no data on use during pregnancy and lactation are available, its use is generally not recommended as a precaution due to lack of experimental data. Even if no side effects are known, it is recommended not to use the product during pregnancy or breastfeeding. In any case, consult your doctor before taking it. In the event of concomitant pharmacological treatment, although no interactions with drugs are known, it is advisable to consult a doctor before use. Do not exceed the recommended daily dose. The period of validity after the first opening of the syrup is 6 months.

Marché principal en Portugal ; disponible dans 1 pays au total.

Dénomination commerciale

non renseigné

Code d'UDI-DI

08056300621515

Basic UDI-DI

805630062FTPR449L

Numéro de référence/catalogue

FTPR44

Entité d'attribution

GS1

Catégorie de risque

Classe IIa

Législation applicable

MDR [Règlement (UE) 2017/745 relatif aux dispositifs médicaux]

Statut

Sur le marché

Quantité

1

Description complémentaire du produit

ZERO COUGH FAMILY SYRUP is a medical device composed of substances, not sterile, intended for short term invasive contact with respect to body orifices (oral cavity), designed for the treatment of productive and dry cough in adults and children (1+). Its specific formula creates a mucoadhesive protective film with a barrier effect in the throat. In case of dry cough, ZERO COUGH FAMILY SYRUP calms the cough by protecting the mucosa from irritating agents. In the case of a productive cough, it promotes the hydration of the mucus and facilitates its physiological expectoration. The product can be used as coadjuvant for the treatment of dry and productive cough.

URL des informations complémentaires

Aucune URL d'informations complémentaires renseignée par le fabricant.

Dimensions cliniques

Aucune dimension clinique enregistrée pour ce dispositif.

Nomenclature européenne des dispositifs médicaux — la classification produit UE attribuée à ce dispositif.

• V9017ORAL ADMINISTRATION PREPARATIONS NOT INCLUDED IN OTHER CLASSES